{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:34:08Z","timestamp":1792852448914,"version":"4.5.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"\n Importance<\/jats:title>\n Significant weight gain is a concerning adverse effect of antipsychotic medications experienced by patients with schizophrenia spectrum disorders (SSDs). Its high prevalence and significant contribution to cardiometabolic morbidity in this population warrant better consensus on the management of antipsychotic-induced weight gain and related comorbidity.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To evaluate the association between pharmacological interventions and changes in body weight among antipsychotic-treated patients with SSDs.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n Ovid MEDLINE, Embase, PsycINFO, the Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP) Search Portal were searched up to December 5, 2025.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Randomized clinical trials examining any pharmacological intervention for weight reduction in antipsychotic-treated patients with SSDs were included. No restrictions to study duration were applied.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n A systematic review and frequentist random-effects network meta-analysis was conducted. Certainty in the evidence was assessed using the Confidence in Network Meta-Analysis (CINeMA) tool. The first round of data analysis took place between May 2025 to November 2025 and was updated in December 2025.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was change in body weight following treatment with pharmacological agent vs placebo or standard care. Secondary outcomes included other anthropometric and metabolic parameters.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 95 studies examining 39 individual pharmacological interventions were included in this review (pooled N\u2009=\u20095898). The network meta-analysis found that semaglutide (mean difference [MD], \u221210.98 kg; 95% CI, \u221213.33 to \u22128.62; k\u2009=\u20093; moderate certainty), liraglutide (MD, \u22125.43 kg; 95% CI, \u22128.54 to \u22122.33; k\u2009=\u20092; moderate certainty), topiramate (MD, \u22123.95 kg; 95% CI, \u22125.89 to \u22122.02; k\u2009=\u20095; moderate certainty), metformin (MD, \u22123.86 kg; 95% CI, \u22125.02 to \u22122.70; k\u2009=\u200916; moderate certainty), and exenatide (MD, \u22122.97 kg; 95% CI, \u22125.83 to \u22120.11; k\u2009=\u20093; moderate certainty) were associated with the most significant reductions in body weight compared to placebo. Other interventions including ramelteon, nizatidine, and aripiprazole were also found to be associated with weight-reducing effects but with very low certainty of evidence. Clinically meaningful weight change of 5% or greater was observed with semaglutide and metformin. Beneficial effects on other metabolic outcomes were also noted with several of the medications, and there were no major concerns with gastrointestinal adverse effects or leaving the study early (ie, dropouts) between interventions.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This systematic review and network meta-analysis found substantial variability in weight-related outcomes across pharmacological interventions for antipsychotic-treated individuals with SSDs. Semaglutide, liraglutide, topiramate, metformin, and exenatide were associated with the greatest reductions in body weight and were supported by the highest-certainty evidence, providing guidance for clinicians managing antipsychotic-associated weight gain.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2026.1814","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:30:21Z","timestamp":1783524621000},"page":"912","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics"],"prefix":"10.1001","volume":"83","author":[{"given":"Nicolette","family":"Stogios","sequence":"first","affiliation":[{"name":"Schizophrenia Division, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Mahavir","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Schizophrenia Division, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Banting and Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada"},{"name":"Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Maksyutynska","sequence":"additional","affiliation":[{"name":"Schizophrenia Division, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halima","family":"Faisal","sequence":"additional","affiliation":[{"name":"Schizophrenia Division, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada"},{"name":"Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lora Lee","family":"Pless","sequence":"additional","affiliation":[{"name":"Department of Medicine, Center for Genomic Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Pillinger","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King\u2019s College London, London, United Kingdom"},{"name":"South London and Maudsley NHS Foundation Trust, Maudsley Hospital, Denmark Hill, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailey","family":"Humber","sequence":"additional","affiliation":[{"name":"Schizophrenia Division, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada"},{"name":"Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie H.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[{"name":"Schizophrenia Division, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy E. J.","family":"Faulkner","sequence":"additional","affiliation":[{"name":"School of Kinesiology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret K.","family":"Hahn","sequence":"additional","affiliation":[{"name":"Schizophrenia Division, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Banting and Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada"},{"name":"Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1-3","key":"yoi260034r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2010.05.025","article-title":"Schizophrenia, \u201cjust the facts\u201d 5. treatment and prevention. past, present, and future.","volume":"122","author":"Tandon","year":"2010","journal-title":"Schizophr Res"},{"issue":"2","key":"yoi260034r2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"issue":"1","key":"yoi260034r3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1517\/14740338.2015.974549","article-title":"Weight gain and antipsychotics: a drug safety review.","volume":"14","author":"Musil","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"yoi260034r4","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1152\/ajpendo.00164.2018","article-title":"Antipsychotics and glucose metabolism: how brain and body collide.","volume":"316","author":"Kowalchuk","year":"2019","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"8","key":"yoi260034r5","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1517\/14740338.2014.935761","article-title":"Safety of antipsychotic drugs: focus on therapeutic and adverse effects.","volume":"13","author":"Werner","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"yoi260034r6","first-page":"645","article-title":"Self-stigma and adherence to medication in patients with psychotic disorders\u2013cross-sectional study.","volume":"35","author":"Vrbov\u00e1","year":"2014","journal-title":"Neuro Endocrinol Lett"},{"issue":"6","key":"yoi260034r7","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1017\/S0033291716003366","article-title":"The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis.","volume":"47","author":"Bora","year":"2017","journal-title":"Psychol Med"},{"issue":"2","key":"yoi260034r8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/acps.13758","article-title":"The impact of weight gain on antipsychotic nonadherence or discontinuation: a systematic review and meta-analysis.","volume":"151","author":"De","year":"2025","journal-title":"Acta Psychiatr Scand"},{"key":"yoi260034r9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.euroneuro.2022.10.001","article-title":"Excess resource use and costs of physical comorbidities in individuals with mental health disorders: a systematic literature review and meta-analysis.","volume":"66","author":"Simon","year":"2023","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"yoi260034r10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1176\/appi.focus.19103","article-title":"The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials.","volume":"19","author":"Vancampfort","year":"2021","journal-title":"Focus (Am Psychiatr Publ)"},{"issue":"6","key":"yoi260034r11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1159\/000502293","article-title":"Lifestyle interventions for weight management in people with serious mental illness: a systematic review with meta-analysis, trial sequential analysis, and meta-regression analysis exploring the mediators and moderators of treatment effects.","volume":"88","author":"Speyer","year":"2019","journal-title":"Psychother Psychosom"},{"issue":"12","key":"yoi260034r12","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1080\/14740338.2019.1674809","article-title":"Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia.","volume":"18","author":"Marteene","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"14","key":"yoi260034r13","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1017\/S0033291716001732","article-title":"Motivating factors and barriers towards exercise in severe mental illness: a systematic review and meta-analysis.","volume":"46","author":"Firth","year":"2016","journal-title":"Psychol Med"},{"issue":"2","key":"yoi260034r14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1192\/bjp.2018.167","article-title":"Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial.","volume":"214","author":"Holt","year":"2019","journal-title":"Br J Psychiatry"},{"key":"yoi260034r15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.genhosppsych.2024.06.003","article-title":"Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: a network meta-analysis.","volume":"90","author":"Hegde","year":"2024","journal-title":"Gen Hosp Psychiatry"},{"issue":"9","key":"yoi260034r16","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1177\/02698811211035391","article-title":"Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: a systematic review and network meta-analysis.","volume":"35","author":"Wang","year":"2021","journal-title":"J Psychopharmacol"},{"key":"yoi260034r17","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.3389\/fphar.2018.01393","article-title":"Topiramate and metformin are effective add-on treatments in controlling antipsychotic-induced weight gain: a systematic review and network meta-analysis.","volume":"9","author":"Zhuo","year":"2018","journal-title":"Front Pharmacol"},{"key":"yoi260034r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2025.152632","article-title":"Comparative effects of pharmacological treatment for weight gain in patients treated with antipsychotics. a systematic review and network meta-analysis.","volume":"143","author":"Goetz-Kundera","year":"2025","journal-title":"Compr Psychiatry"},{"issue":"10","key":"yoi260034r19","article-title":"Pharmacological interventions for prevention of weight gain in people with schizophrenia.","volume":"10","author":"Agarwal","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"yoi260034r20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"3","key":"yoi260034r22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/jrsm.1195","article-title":"GetReal in network meta-analysis: a review of the methodology.","volume":"7","author":"Efthimiou","year":"2016","journal-title":"Res Synth Methods"},{"issue":"11","key":"yoi260034r23","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"2","key":"yoi260034r24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies.","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"issue":"10434","key":"yoi260034r25","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S0140-6736(24)00351-9","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.","volume":"403","author":"Shi","year":"2024","journal-title":"Lancet"},{"issue":"11","key":"yoi260034r26","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s11920-023-01458-0","article-title":"Antipsychotic-induced weight gain in severe mental illness: risk factors and special considerations.","volume":"25","author":"Stogios","year":"2023","journal-title":"Curr Psychiatry Rep"},{"issue":"1","key":"yoi260034r27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12874-021-01290-1","article-title":"A method for assessing robustness of the results of a star-shaped network meta-analysis under the unidentifiable consistency assumption.","volume":"21","author":"Yoon","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"yoi260034r21","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"McKenzie","year":"2022"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2851585\/jamapsychiatry_stogios_2026_oi_260034_1788289924.42161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:00:32Z","timestamp":1788361232000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2851585"}},"subtitle":["A Systematic Review and Network Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.1814","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}